| Name | Title | Contact Details |
|---|---|---|
David Demsey |
Head Of Information Security and Infrastructure | Profile |
Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.
Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.
Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.
Stelexis` mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).